Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)
Dianthus Therapeutics' quarterly Capital Expenditures came in at $5000.0 in Q3 2025, down 80.0% year-on-year from $25000.0 in Q3 2024, and down 89.13% quarter-over-quarter from $46000.0 in Q2 2025.
Dianthus Therapeutics has reported Capital Expenditures for 9 years, with the latest figure at $5000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures fell 80.0% year-over-year to $5000.0; the trailing twelve-month figure through Sep 2025 stood at $106000.0 (up 26.19% YoY), and the FY2024 full-year result was $105000.0, down 4.55% from the prior year.
- Capital Expenditures for Q3 2025 stood at $5000.0, down from $46000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.1 million in Q3 2021, with the low at -$1.2 million in Q4 2021.
- Average Capital Expenditures over 5 years is $22578.9, with a median of $25000.0 recorded in 2024.
- Peak annual rise in Capital Expenditures reached 5555.0% in 2021, while the deepest fall reached 686.38% in 2021.
- Tracing DNTH's Capital Expenditures over 5 years: stood at -$1.2 million in 2021, then soared by 102.32% to $29000.0 in 2022, then tumbled by 65.52% to $10000.0 in 2023, then surged by 210.0% to $31000.0 in 2024, then slumped by 83.87% to $5000.0 in 2025.
- The last three Capital Expenditures figures came in at $5000.0 (Q3 2025), $46000.0 (Q2 2025), and $24000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | -46,000.00 |
| Sep 30, 2022 | -46,000.00 |
| Jun 30, 2022 | 129,000.00 |
| Jun 30, 2022 | 129,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Dec 31, 2021 | -1.25 Mn |
| Dec 31, 2021 | -1.25 Mn |
| Sep 30, 2021 | 1.13 Mn |
| Sep 30, 2021 | 1.13 Mn |
| Jun 30, 2021 | 111,000.00 |
| Jun 30, 2021 | 111,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Dec 31, 2020 | 213,000.00 |
| Dec 31, 2020 | 213,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Sep 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 36,000.00 |
| Mar 31, 2020 | 131,000.00 |
| Mar 31, 2020 | 131,000.00 |
| Dec 31, 2019 | 153,000.00 |
| Dec 31, 2019 | 153,000.00 |
| Sep 30, 2019 | 2.44 Mn |
| Sep 30, 2019 | 2.44 Mn |
| Jun 30, 2019 | -779,000.00 |
| Jun 30, 2019 | -779,000.00 |
| Mar 31, 2019 | 1.25 Mn |
| Mar 31, 2019 | 1.25 Mn |
| Dec 31, 2018 | -1.78 Mn |
| Dec 31, 2018 | -1.78 Mn |
| Sep 30, 2018 | 2.89 Mn |
| Sep 30, 2018 | 2.89 Mn |
| Jun 30, 2018 | 346,000.00 |
| Jun 30, 2018 | 346,000.00 |
| Mar 31, 2018 | 85,000.00 |
| Mar 31, 2018 | 85,000.00 |
| Dec 31, 2017 | 317,000.00 |
| Dec 31, 2017 | 317,000.00 |
| Sep 30, 2017 | 385,000.00 |
| Sep 30, 2017 | 385,000.00 |